Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology
Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.
You may also be interested in...
Coherus BioSciences’ plans earlier this month to launch its Humira biosimilar, Yusimry, at a massive discount have sparked both a legal battle and an arrangement with a “next generation” pharmacy benefit manager.
Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.
Amid deepening bilateral decoupling and geopolitical tensions, the US regulatory agency is sending field inspectors to China for the first time in three years as it moves forward in reviewing and potentially approving the first 'Made In China' immuno-oncology drugs.